Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

Zymeworks News

Aktie
WKN:  A3DSSN ISIN:  US98985Y1082 US-Symbol:  ZYME Branche:  Biotechnologie Land:  USA
22,70 €
+0,00 €
0,00%
16:36:34 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,57 Mrd. €
Streubesitz
-
KGV
-9,04
Index-Zuordnung
-

Zymeworks News

21.04.26 - GlobeNewswire
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
ZW191 demonstrates encouraging anti-​tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) ...
17.04.26 - GlobeNewswire
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Six poster presentations showcase Zymeworks’ next-​generation ADC programs, including multiple first-​in-class pan-RAS inhibitor ADCs  Data highlight efficacy, tumor-​selective ...
09.04.26 - GlobeNewswire
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer
01.04.26 - GlobeNewswire
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare ...
30.03.26 - GlobeNewswire
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
U.S. FDA Fast Track designation granted to ZW191, an antibody-​drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-...
18.03.26 - GlobeNewswire
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology
17.03.26 - GlobeNewswire
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha ...
02.03.26 - GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks to receive $250 million under a royalty-​backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully ...
27.01.26 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare ...
12.01.26 - GlobeNewswire
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood ...
12.01.26 - GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Positive Phase 3 HERIZON-​GEA-01 results for Ziihera ® (zanidatamab-​hrii) in first-​line HER2-positive (HER2+)  gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI ...
06.01.26 - GlobeNewswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Positive results from Phase 3 HERIZON-​GEA-01 results support Ziihera as the HER2-targeted agent-​of-choice in HER2+ first-​line metastatic GEA and Ziihera plus chemotherapy to ...
18.11.25 - GlobeNewswire
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare ...
18.11.25 - GlobeNewswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results ...
17.11.25 - GlobeNewswire
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful ...
23.10.25 - GlobeNewswire
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-...
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
13.10.25 - GlobeNewswire
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-​NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, ...
09.10.25 - GlobeNewswire
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »